Sector News

Takeda makes an M&A move in Turkey

February 25, 2015
Life sciences
Takeda’s CEO-in-waiting, Christophe Weber, has included emerging markets, along with oncology and gastrointestinal medicines, as one of three areas of focus for the Japanese drugmaker. He recently said he is ready to do some deals to capitalize on those areas, and now he has executed one that straddles two of those favorites.
 
Osaka, Japan-based Takeda announced today that it would pay 300 million Turkish lira ($121 million) to buy a portfolio of 13 drugs from Neutec, one of the top drugmakers in Turkey. It said the baker’s dozen of drugs include products for treating gastrointestinal conditions, as well as respiratory, metabolic and musculoskeletal conditions. The drugmaker said it expects to close the all-cash deal, which would reach the 300 million lira mark based on milestones, this quarter. Istanbul-based Neutec will continue to manufacture the products at its plant in Adapazari.
 
Danilo Cassani, who oversees Takeda’s operations in the Near East, Middle East and Africa, pointed out that the Turkey pharma market is set to grow by 6% a year over the next 5 years, a faster pace than most developed countries. Other drugmakers, like Sanofi ($SNY), have also tagged it as a good bet. Takeda has been plumbing this market for about 5 years and has 130 employees there selling a portfolio of its own drugs, including diabetes treatment Actos. Takeda will add another 100 positions in the country with the closure of this deal.
 
Weber became Takeda’s chief operating officer last year and was selected by CEO Yasuchika Hasegawa to be his replacement when he relinquishes the CEO role in June. The outsider is charged with remaking Takeda into an international player, and toward that end, Weber has been reorganizing the company. Last month he said that with the reorg in action, he was prepared to consider some deals to bolster Takeda’s target areas. He said he didn’t intend for the company to be passive and just “watch the train passing.”
 
By Eric Palmer
 
 

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).